Mannkind said it is creating an inhaled formulation of ralinepag, an experimental oral pulmonary arterial hypertension (PAH) treatment, for developer United Therapeutics. The inhaled version, ralinepag DPI, will be a dry powder that delivers the drug directly to the lungs, providing an alternative to the tablet formulation. The…
Treatment with treprostinil, a medicine that relaxes blood vessels, led to significant and sustained improvements in children with pulmonary hypertension (PH) caused by different lung conditions, according to a retrospective analysis. Findings from the analysis were detailed in the study, “Treprostinil Is Associated With Early and Sustained Improvement…
A team of scientists in China identified four genes that may serve as potential treatment targets for idiopathic pulmonary arterial hypertension (PAH). “This study combined [computer-based genetic sequencing] analyses with experimental validation [in cell and animal models] to identify COL1A1, MYL9, COL1A2, and TPM2 as potential key driver genes…
Scientists in China have developed a phosphodiesterase-5 (PDE5) inhibitor for pulmonary arterial hypertension (PAH) that reduced disease severity in a rat model of PAH. The scientists detailed the development and testing of the treatment, CPD1, in a study that also shed light on the molecular mechanisms through which the…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
